Ovid Therapeutics is a cash-burning, near-pre-revenue biotech with large analyst-implied upside and a pullback within a rising trend, but quality is below the floor and leverage is flagged as high.
Thesis pillars
- Large Analyst Upside→Stable
- Severe Cash Burn→Stable
- Pullback In Rising Trend↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 18, 2026
Ovid Therapeutics Inc. (OVID) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality.
Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders driven by neuronal hyperexcitability, including OV329, a GABA-aminotransferase inhibitor in Phase 1 development for drug-resistant seizures, and a KCC2... Read more
Sell if holding. Engine safety override at $2.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Ovid Therapeutics Inc.
About Ovid Therapeutics Inc.
Ovid Therapeutics has no approved drugs and no product revenue, funding its neuroscience pipeline with $90.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which the company expects will cover operations for at least the next 12 months. Its lead clinical program, OV329, a GABA-aminotransferase inhibitor for drug-resistant seizures, has completed Phase 1 dosing with regulatory discussions underway for Phase 2, while OV4071, the lead candidate from Ovid's KCC2 direct-activator library, is expected to begin a Phase 1 trial in the second quarter of 2026 for psychosis associated with Parkinson's disease and Lewy body dementia.
Since it has no marketed products, Ovid generates no revenue and instead builds its pipeline primarily through in-licensing and business development rather than internal discovery; the company has assembled five clinical-stage programs targeting epilepsy, developmental and epileptic encephalopathies, and psychosis tied to Parkinson's disease, Lewy body dementia, and schizophrenia. OV329 targets an already-validated GABA-AT mechanism and is designed to improve on vigabatrin, an older approved anti-seizure drug limited by irreversible vision-loss side effects, while the KCC2 library, built from more than 100 in-house molecules, addresses a target the company says is uniquely expressed in the central nervous system. Ovid reported a $17.4 million net loss for 2025 against a $321.7 million accumulated deficit, reflecting years of preclinical and clinical spending with no offsetting product sales.
Show full overview
Ovid's disclosed cash runway of approximately 12 months from its financial statement issuance date is shorter than the multi-year runway many clinical-stage peers report, meaning the company may need to raise additional capital, through equity, debt, or a licensing partnership, before either of its lead programs, OV329 or OV4071, reaches a late-stage readout. The 10-K also flags reliance on third-party manufacturers for all clinical and prospective commercial drug supply, since Ovid has no in-house manufacturing capability of its own.
See also: Healthcare · Biotechnology
From Ovid Therapeutics Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Ovid Therapeutics Inc.
Latest news
- NEWS Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5 — benzinga Oct 15, 2026 positive
- NEWS Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating — benzinga Oct 9, 2026 positive
- NEWS Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 — benzinga Oct 6, 2026 positive
- NEWS Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session — benzinga Sep 29, 2026 neutral
- NEWS Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate — benzinga Aug 13, 2026 positive
Generated 2026-10-29T11:08:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-03Item 5.02LOWOvid's Board approved an increase in board size and the appointment of Dr. Anna Greka, a Harvard Medical School professor, as a Class III director effective June 15, 2026, with a term expiring at the 2029 annual meeting. Dr. Greka was also named to the Compensation and Science and Technology Committees; no departure or replacement was involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.45: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $2.28. Score 5.9/10, moderate confidence.
Analyst target: $5.57 (+127.3% upside). Prior stop was $2.28. Stop-loss: $2.28.
Quality below floor (3.1 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.1), Material insider selling (53 sells, 0.75% of cap).
Ovid Therapeutics Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover OVID with a consensus score of 4.4/5. Average price target: $6.
What does Ovid Therapeutics Inc. do?Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders...
Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders driven by neuronal hyperexcitability, including OV329, a GABA-aminotransferase inhibitor in Phase 1 development for drug-resistant seizures, and a KCC2 direct-activator platform, led by OV4071, targeting psychosis associated with Parkinson's disease and Lewy body dementia. The company has no products approved for commercial sale and has never generated product revenue, reporting a $17.4 million net loss for 2025 against an accumulated deficit of $321.7 million, with $90.4 mil